Ignite Creation Date:
2025-12-25 @ 2:04 AM
Ignite Modification Date:
2026-02-23 @ 1:10 AM
Study NCT ID:
NCT02220660
Status:
COMPLETED
Last Update Posted:
2014-08-20
First Post:
2014-08-19
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Free Combination of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers
Sponsor:
Boehringer Ingelheim
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2009-03
Start Date Type:
None
Primary Completion Date:
2009-06
Primary Completion Date Type:
ACTUAL
Completion Date:
None
Completion Date Type:
None
First Submit Date:
2014-08-19
First Submit QC Date:
None
Study First Post Date:
2014-08-20
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2014-08-19
Last Update Post Date:
2014-08-20
Last Update Post Date Type:
ESTIMATED